Phase 3 clinical trial of Abbvie Rinvoq (upadacitinib) for psoriasis arthritis reaches primary and secondary endpoint

today, AbbVie(http:// announcedthat its JAK1-specific inhibitor, Rinvoq (upadacitinib), reached the primary and primary secondary end of the trial in the Phase 3 clinicaltrial(http://SELECT-PsA 2 for adult patients with active psoriasis arthritisAbout Rinvoq
Rinvoq is a small molecule JAK1 selective inhibitor that is taken orally once a dayPreviously, theFDA(http://approved for the treatment of adult patients with moderate to severe active rheumatoid arthritis (active RA)Rinvoq is also conducting clinical studies on a number of inflammatory indications, including psoriasis arthritis, Crohn's disease, ulcerative colitis, hypercystosis, and adhesion dermatitisFor SELECT-PsA 2patients in phase 3 trials called SELECT-PsA 2, including placebo-controlled groups, patients were treated with one or more biologic anti-rheumaticdrug(http://(bDMARDs), but the treatment was poorly performedThe results showed that after 12 weeks of treatment, the proportion of patients who received ACR20 (one of the american rheumatology assessment synods) in patients receiving two different doses of Rinvoq (15 mg or 30 mg) was 57% and 64%, respectively, compared with 24% in the placebo group, which reached the main therapeutic end of the trialAfter 12 weeks of treatment, the proportion of patients who reached ACR50 in the treatment group was 32% and 38%, respectively, compared with 5% in the placebo groupThe proportion of patients who achieved ACR70 in the treatment group was 9% and 17%, respectively, compared with 0.5% in the placebo group